Influence of angiotensin II on circulating adhesion molecules and blood leukocyte count in vivo.

The mechanism of the beneficial effect of angiotensin converting enzyme inhibitors in patients with myocardial infarction is not clear. Recent in vitro data indicate that angiotensin II (AII) stimulates the expression of adhesion molecules and thus activates leukocyte endothelial interactions. In eight healthy volunteers we investigated the influence of exogenous AII on circulating adhesion molecules and on the blood leukocyte count. A systemically effective and a systemically ineffective dose of AII were administered intravenously over 4 h in a single blind crossover design. Examination of the time course of circulating intercellular and vascular adhesion molecules and E-selectin (cICAM-1, cVCAM-1, cE-selectin-1) in response to the AII infusion revealed increases of up to 11% (especially in cVCAM-1 levels) at single time points, but no significant sustained elevation or trend that can be interpreted as a drug-induced effect. The systemically effective dose, which induced an increase in mean arterial blood pressure from 80 to 108 mmHg (1 mmHg = 133.3 Pa), resulted in a significant increase in blood leukocytes, from 4.8 +/- 0.3 to 5.5 +/- 0.3 g/L (p < 0.05); the systemically ineffective AII dose did not alter blood leukocyte count significantly. Although we did not find an influence of AII on circulating adhesion molecules in vivo, we observed an increase in the blood leukocyte count; thus it may be intriguing to assess whether renin-angiotensin system modulating drugs might exert their favorable effect in ischemic diseases at least in part via an influence on leukocytes.

[1]  K. Krejcy,et al.  Effects of exercise on circulating vascular adhesion molecules in healthy men. , 1997, Immunobiology.

[2]  M. Wolzt,et al.  Effects of 17 beta-estradiol on circulating adhesion molecules. , 1994, The Journal of clinical endocrinology and metabolism.

[3]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  GISSI-3: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction , 1994, The Lancet.

[4]  G. Canonica,et al.  Adhesion molecules of allergic inflammation: recent insights into their functional roles , 1994, Allergy.

[5]  J. Holtz,et al.  The endothelium and the renin-angiotensin system. , 1994, Arzneimittel-Forschung.

[6]  K. Reimann,et al.  Kinetic expression of endothelial adhesion molecules and relationship to leukocyte recruitment in two cutaneous models of inflammation. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[7]  D. Altavilla,et al.  E-selectin in the pathogenesis of experimental myocardial ischemia-reperfusion injury. , 1994, European journal of pharmacology.

[8]  M. Davies,et al.  The expression of the adhesion molecules ICAM‐1, VCAM‐1, PECAM, and E‐selectin in human atherosclerosis , 1993, The Journal of pathology.

[9]  A. Gearing,et al.  Circulating adhesion molecules in disease. , 1993, Immunology today.

[10]  R. Brezinschek,et al.  Increased immune activation during and after physical exercise. , 1993, Immunobiology.

[11]  P. Timmermans,et al.  Angiotensin II receptors and angiotensin II receptor antagonists. , 1993, Pharmacological reviews.

[12]  P. Ridker,et al.  Stimulation of Plasminogen Activator Inhibitor In Vivo by Infusion of Angiotensin II Evidence of a Potential Interaction Between the Renin‐Angiotensin System and Fibrinolytic Function , 1993, Circulation.

[13]  Mike D Cadogan,et al.  The distribution of adhesion molecules in human atherosclerosis , 1993, Histopathology.

[14]  M. Chilosi,et al.  ICAM‐1 tissue overexpression associated with increased serum levels of its soluble form in Hodgkin's disease , 1993, British journal of haematology.

[15]  C. Smith,et al.  Leukocyte-endothelial cell adhesion in spontaneously hypertensive and normotensive rats. , 1993, Hypertension.

[16]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[17]  M P Bevilacqua,et al.  Endothelial-leukocyte adhesion molecules. , 1993, Annual review of immunology.

[18]  W. Sluiter,et al.  Leukocyte adhesion molecules on the vascular endothelium: their role in the pathogenesis of cardiovascular disease and the mechanisms underlying their expression. , 1993, Journal of cardiovascular pharmacology.

[19]  V. Dzau,et al.  Vascular renin-angiotensin system and vascular protection. , 1993, Journal of cardiovascular pharmacology.

[20]  S. J. Cashman,et al.  Soluble Forms of Vascular Adhesion Molecules, E‐Selectin, ICAM‐1, and VCAM‐1: Pathological Significance , 1992, Annals of the New York Academy of Sciences.

[21]  J. Neefjes,et al.  E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. , 1992, Immunology.

[22]  A. Gearing,et al.  Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. , 1992, Biochemical and biophysical research communications.

[23]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[24]  A. M. Lefer,et al.  Coronary Endothelial and Cardiac Protective Effects of a Monoclonal Antibody to Intercellular Adhesion Molecule‐1 in Myocardial Ischemia and Reperfusion , 1992, Circulation.

[25]  J. Coucher,et al.  Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. , 1992, The American journal of pathology.

[26]  D. V. Van Epps,et al.  In vitro models of lymphocyte transendothelial migration. , 1992, Invasion & metastasis.

[27]  W. Dietz,et al.  Reference data for obesity: 85th and 95th percentiles of body mass index (wt/ht2)—a correction , 1991 .

[28]  G. Specchia,et al.  Role of granulocytes in endothelial injury in coronary heart disease in humans. , 1991, Atherosclerosis.

[29]  T. Matsukawa,et al.  Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans. , 1991, The American journal of physiology.

[30]  K Lindpaintner,et al.  The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. , 1991, Circulation research.

[31]  S. Gasic,et al.  Contribution of Splanchnic and Peripheral Vascular Tissues to the Disposal of Angiotensin‐II and to Regional Conversion Rates of Angiotensin‐I: A Pilot Study in Humans , 1991, Journal of cardiovascular pharmacology.

[32]  F. Delano,et al.  Leukocyte Counts and Activation in Spontaneously Hypertensive and Normotensive Rats , 1991, Hypertension.

[33]  M. Ambrosio,et al.  Stimulation of growth hormone and corticotropin release by angiotensin II in man. , 1990, Metabolism: clinical and experimental.

[34]  G. Specchia,et al.  Granulocyte activation after coronary angioplasty in humans. , 1990, Circulation.

[35]  Effect of angiotensin II infusion on the human glomerular filtration barrier. , 1989, The American journal of physiology.

[36]  S. Podolsky,et al.  Renin suppression by saline is blunted in nonmodulating essential hypertension. , 1987, Hypertension.

[37]  Leukocytes and the risk of ischemic diseases. , 1987, JAMA.

[38]  H. Dargie,et al.  Neuroendocrine Activation in Acute Myocardial Infarction , 1987, Journal of cardiovascular pharmacology.

[39]  R. Ross.  The pathogenesis of atherosclerosis--an update. , 1986, The New England journal of medicine.

[40]  H. Farber,et al.  Bovine and human endothelial cell production of neutrophil chemoattractant activity in response to components of the angiotensin system. , 1985, Circulation research.

[41]  N. Hollenberg,et al.  Relation of the Renin‐Angiotensin-Aldosterone System to Clinical State in Congestive Heart Failure , 1981, Circulation.